Ischaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients
- 1 January 2011
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 106 (07) , 34-44
Abstract
Summary: Stroke prevention guidelines recommend oral anticoagulants (OAC) for atrial fibrillation (AF) patients at moderate/high risk of stroke, and antiplatelet or no therapy for those at low/moderate risk. Outcomes for AF patients receiving antiplatelet/no therapy in ‘real-life’ clinical practice were explored. This study compared clinical event rates (stroke/bleeding) for AF patients treated with OAC therapy, antiplatelets or no therapy in usual clinical practice to event rates in OAC-treated AF patients from optimally-monitored ‘real-life’ settings (anticoagulation clinics). We searched biomedical literature (1994–2010) using PubMed to identify ‘real-world’ studies of clinical event rates for AF patients receiving OAC therapy, antiplatelets, or no therapy; event rates were extracted for each treatment and setting. We identified 136 studies of thromboembolic events and 86 of bleeding events. Ischaemic stroke rates (30 studies) were higher for AF patients receiving no therapy (median: 4.45/100 person-years; range: 0.25–5.9) or antiplatelet-therapy (median: 4.45/100 person-years; range: 2.0–10) compared to OACtreated patients monitored in anticoagulation clinics (median: 1.72/100 person-years; range: 0.97–2.00), or from a non-specialized setting (median 1.66/100 person-years; range: 0–4.9). Major bleeding rates (32 studies) for patients receiving antiplatelet/no therapy were similar to OAC-treated patients from both clinical settings. As in randomised clinical trials, AF patients in ‘real-world’ clinical practice receiving antiplatelet/no therapy have higher rates of ischaemic stroke than OAC-treated patients. Antiplatelet/no therapy was associated with similar bleeding rates to OAC therapy. Increasing utilisation of anticoagulants in clinical practice could improve patient outcomes.Keywords
Funding Information
- Bayer HealthCare
This publication has 79 references indexed in Scilit:
- Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert systemJournal of Thrombosis and Haemostasis, 2009
- How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-ValvularAtrial Fibrillation?Yonsei Medical Journal, 2009
- Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial FibrillationThe American Journal of Cardiology, 2009
- Application of a Decision Support Tool for Anticoagulation in Patients with Non-valvular Atrial FibrillationJournal of General Internal Medicine, 2008
- Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial FibrillationJACC, 2008
- Predicción de eventos embólicos en pacientes con fibrilación auricular no valvular: evaluación del score CHADS2 en una población mediterráneaRevista Espanola de Cardiologia, 2008
- Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation StudyJournal of the American Geriatrics Society, 2006
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Culprit Factors for the Failure of Well-Conducted Warfarin Therapy to Prevent Ischemic Events in Patients With Atrial FibrillationStroke, 2005
- Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarinHeart, 2005